Details of the Metabolic Reaction (MR)

General Information of This Metabolic Reaction (MR) (ID: MR010786)
Formula
SVG example
Unclear
Reactant Naloxone Metabolite M2 Product Naloxone Metabolite M35
Reactant Info Product Info
Metabolic Type Unclear - Unclear
Other MR(s) Related to The Reactant of This MR
Other MR(s) That Produce The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010785 Naloxone Naloxone Metabolite M2 Unclear - Unclear Naloxone [1]
MR001898 Oxymorphone Noroxymorphone Oxidation - N-Demethylation Oxymorphone [2]
MR001878 Noroxycodone Noroxymorphone Oxidation - N-Demethylation Oxycodone hydrochloride [3], [4]
MR013819 Noroxycodone Noroxymorphone Unclear - Unclear Oxycodone [5]
MR001886 Oxymorphone Noroxymorphone Oxidation - N-Demethylation Oxycodone hydrochloride [6]
MR013821 Oxymorphone Noroxymorphone Unclear - Unclear Oxycodone [5]
MR010778 Zanubrutinib Metabolite M3/M11 Zanubrutinib Metabolite M2 Unclear - Unclear zanubrutinib [7]
⏷ Show the Full List of MR
Other MR(s) That Metabolize The Reactant of This MR
MR ID Reactant Product MR Type Related Drug REF
MR010780 Zanubrutinib Metabolite M2 Zanubrutinib Metabolite M1 Unclear - Unclear zanubrutinib [7]
⏷ Show the Full List of MR
References
1 Optimization of Mass Spectrometry Imaging for Drug Metabolism and Distribution Studies in the Zebrafish Larvae Model: A Case Study with the Opioid Antagonist Naloxone
2 Exposure to oral oxycodone is increased by concomitant inhibition of CYP2D6 and 3A4 pathways, but not by inhibition of CYP2D6 alone. Br J Clin Pharmacol. 2010 Jul;70(1):78-87.
3 Quantitative contribution of CYP2D6 and CYP3A to oxycodone metabolism in human liver and intestinal microsomes. Drug Metab Dispos. 2004 Apr;32(4):447-54.
4 Enzalutamide Reduces Oxycodone Exposure in Men with Prostate Cancer. Clin Pharmacokinet. 2023 May 10. doi: 10.1007/s40262-023-01255-1.
5 Metabolism and Disposition of Prescription Opioids: A Review
6 DrugBank(Pharmacology-Metabolism)Oxycodone hydrochloride
7 In vitro investigations into the roles of CYP450 enzymes and drug transporters in the drug interactions of zanubrutinib, a covalent Bruton's tyrosine kinase inhibitor

If you find any error in data or bug in web service, please kindly report it to Dr. Yin and Dr. Li.